
|Videos|January 23, 2014
The Future of Bladder Cancer
Author(s)Arjun Balar, MD
Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the future of bladder cancer.
Advertisement
Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the future of bladder cancer.
Clinical Pearls:
- Within the next 10 years, physicians will have hopefully moved away from using chemotherapy to treat patients with bladder cancer
- Physicians need to refine their understanding of the genetic makeup of bladder cancer in order identify validating predictive biomarkers
- Hopefully in the future, physicians will be able to biopsy a tumor in real time, identify actionable alterations in the patient’s tumor, and select a particular therapy based on the findings
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5








































